
NSF Org: |
MCB Division of Molecular and Cellular Biosciences |
Recipient: |
|
Initial Amendment Date: | June 9, 2020 |
Latest Amendment Date: | June 9, 2020 |
Award Number: | 2033939 |
Award Instrument: | Standard Grant |
Program Manager: |
Richard Cyr
rcyr@nsf.gov (703)292-8440 MCB Division of Molecular and Cellular Biosciences BIO Directorate for Biological Sciences |
Start Date: | June 15, 2020 |
End Date: | May 31, 2021 (Estimated) |
Total Intended Award Amount: | $199,844.00 |
Total Awarded Amount to Date: | $199,844.00 |
Funds Obligated to Date: |
|
History of Investigator: |
|
Recipient Sponsored Research Office: |
10550 N TORREY PINES RD LA JOLLA CA US 92037-1000 (858)784-8653 |
Sponsor Congressional District: |
|
Primary Place of Performance: |
130 Scripps Way, 2C1 Jupiter FL US 33458-5284 |
Primary Place of
Performance Congressional District: |
|
Unique Entity Identifier (UEI): |
|
Parent UEI: |
|
NSF Program(s): | COVID-19 Research |
Primary Program Source: |
|
Program Reference Code(s): |
|
Program Element Code(s): |
|
Award Agency Code: | 4900 |
Fund Agency Code: | 4900 |
Assistance Listing Number(s): | 47.074 |
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, single-stranded RNA virus that belongs to the subgenus sarbecvirus of Coronaviridae. Members of the Coronaviridae family include the SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV), which are the responsible human pathogens for the common cold and other emerging severe respiratory conditions. SARS-CoV and SARS-CoV-2 attach to the host cells by binding to the angiotensin converting enzyme 2 (ACE2) receptor. Viral entry is facilitated by the binding of the receptor binding domain (RBD) of the coronavirus spike protein to the ACE2 receptor. However, SARS-CoV-2 targets type II alveolar cells in the lung that have relatively low ACE2 expression compared to ACE2 expression in other organs. Thus, other co-receptors have been identified that are targeted by the virus and which likely provide for an alternative entry point for the virus. While SARS-CoV-2 infects fewer organs compared to SARS-CoV, the mechanisms remain inconclusive. This research project will provide structural insights into the novel role of a human cell surface protein in SARS-CoV-2 entry and replication. There is an urgent need for gaining insight into this possible second entry point for the virus into cells. Additionally, this project includes an educational outreach component geared towards the underrepresented minorities and in particular the younger population, an incredibly important sub popular who might be underestimating the impact of SARS.
This research project will use the first 300 kV cryo Atomic Resolution Microscope (ARM), installed to date in the US, to determine the near atomic resolution structures of the novel interaction between a human cell surface protein and the SARS-CoV-2 spike protein. Biochemical assays will additionally validate the structural findings. Thus, significant mechanistic insights into viral pathogenesis will be published rapidly from data obtained on a new cryo-electron microscope in the US that has aided near atomic resolution insights into many biological processes from several laboratories overseas, including from Europe and Asia. By determining the mechanistic insights into how SARS-CoV-2 infects fewer organs compared to SARS-CoV, the findings obtained in this research project could explain the lower mortality of SARS-CoV-2 compared to SARS-CoV. Collectively, the structural insights into the mechanism of the interaction of the SARS-CoV-2 spike protein with a human cell surface protein will: (i) further the understanding on how COVID-19 is spreading, (ii) shed light onto some of the key differences of SARS-CoV-2 versus SARS-CoV, and (iii) provide mechanistic insights into the higher transmissibility of SARS-CoV-2. Such virus-host study will contribute to a broader understanding of viral pathogenesis.
This RAPID award is made by the Cellular Dynamics and Functionl Program in the Division of Molecular and Cellular Biosciences, using funds from the Coronavirus Aid, Relief, and Economic Security (CARES) Act.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
PUBLICATIONS PRODUCED AS A RESULT OF THIS RESEARCH
Note:
When clicking on a Digital Object Identifier (DOI) number, you will be taken to an external
site maintained by the publisher. Some full text articles may not yet be available without a
charge during the embargo (administrative interval).
Some links on this page may take you to non-federal websites. Their policies may differ from
this site.
PROJECT OUTCOMES REPORT
Disclaimer
This Project Outcomes Report for the General Public is displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed in this Report are those of the PI and do not necessarily reflect the views of the National Science Foundation; NSF has not approved or endorsed its content.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, single-stranded RNA virus that belongs to the subgenus sarbecvirus of Coronaviridae. Members of the Coronaviridae family include the SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV), which are the responsible human pathogens for the common cold and other emerging severe respiratory conditions. SARS-CoV and SARS-CoV-2 attach to the host cells by binding to the angiotensin converting enzyme 2 (ACE2) receptor. Viral entry is facilitated by the binding of the receptor binding domain (RBD) of the coronavirus spike protein to the ACE2 receptor. However, SARS-CoV-2 targets type II alveolar cells in the lung that have relatively low ACE2 expression compared to ACE2 expression in other organs. Thus, other co-receptors have been identified that are targeted by the virus. While SARS-CoV-2 infects fewer organs compared to SARS-CoV, the mechanisms remain inconclusive. This research project sought to provide structural insights into the role a new and understudied human cell surface protein in SARS-CoV-2 entry and replication. Additionally, this project includes an educational outreach component geared towards the underrepresented minorities and in particular the younger population, an incredibly important sub popular who might be underestimating the impact of SARS.
While we could not confirm the interaction of the spike protein with integrin, we showed that the genetic point mutation D614G of the spike protein increases the ability of the coronavirus to infect human cells.
We published our findings in a peer reviewed journal in 2020 (Nature Communications, 11:6013) and our work was highlighted in a press release:
https://www.scripps.edu/news-and-events/press-room/2020/20200612-choe-farzan-coronavirus-spike-mutation.html
Last Modified: 09/24/2021
Modified by: Tina Izard
Please report errors in award information by writing to: awardsearch@nsf.gov.